var data={"title":"Vincristine (conventional): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vincristine (conventional): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7152?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">see &quot;Vincristine (conventional): Drug information&quot;</a> and <a href=\"topic.htm?path=vincristine-conventional-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vincristine (conventional): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708854\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:4em;\">Vincristine should be administered by individuals experienced in the administration of the drug. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Extravasation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">It is extremely important that the intravenous (IV) needle or catheter be properly positioned before any vincristine is injected. Leakage into surrounding tissue during IV administration may cause considerable irritation. If extravasation occurs, discontinue the injection immediately and then introduce any remaining portion of the dose into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage will help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Not for intrathecal use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">For IV use only. Fatal if given by other routes. The intrathecal administration of vincristine usually results in death.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Syringes containing this product should be labeled, using the auxiliary sticker provided, to state, &ldquo;For intravenous use only. Fatal if given by other routes.&rdquo; Extemporaneously prepared syringes containing this product must be packaged in an overwrap that is labeled, &ldquo;Do not remove covering until moment of injection. For intravenous use only. Fatal if given by other routes&quot;.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of patients following intrathecal administration of vincristine has included immediate removal of spinal fluid and flushing with Ringer's lactate solution, as well as other solutions, and has not prevented ascending paralysis and death. In one case, progressive paralysis in an adult was arrested by the following treatment initiated immediately after the intrathecal injection:</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">As much spinal fluid was removed as could be safely done through lumbar access.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">The subarachnoid space was flushed with Ringer's lactate solution infused continuously through a catheter in a cerebral lateral ventricle at the rate of 150 mL/h. The fluid was removed through a lumbar access.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">As soon as fresh frozen plasma became available, the fresh frozen plasma, 25 mL, diluted in 1 L of Ringer's lactate solution was infused through the cerebral ventricular catheter at the rate of 75 mL/h with removal through the lumbar access. The rate of infusion was adjusted to maintain a protein level in the spinal fluid of 150 mg/dL.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Glutamic acid 10 g was given IV over 24 hours followed by 500 mg 3 times daily by mouth for 1 month or until neurological dysfunction stabilized. The role of glutamic acid in this treatment is not certain and may not be essential.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234194\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Vincasar PFS</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10518612\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vincristine Sulfate Injection;</li>\n      <li>Vincristine Sulfate Injection USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050610\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimicrotubular</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Mitotic Inhibitor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Vinca Alkaloid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16342255\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol. In pediatric patients, dosing may be based on either BSA (mg/m<sup>2</sup>) or weight (mg/kg); use extra precaution to verify dosing parameters during calculations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuroblastoma:</b> Limited data available: CE-CAdO regimen:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Newborns: IV: 0.035 mg/<b>kg/dose </b> on day 1, then every 21 days for 2 cycles (Rubie 1998) or on days 1 and 5 for 2 cycles (Rubie 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Older neonates: IV: 0.05 mg/<b>kg/dose</b> on days 1 and 5 for 2 cycles (Rubie 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050602\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">see &quot;Vincristine (conventional): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Doses are almost always capped at a maximum of 2 mg/dose/week (Kushner 2010). Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> In pediatric patients, dosing may be based on either BSA (mg/m<sup>2</sup>) or weight (mg/kg); use extra precaution to verify dosing parameters during calculations. For infants and children &lt;10 kg, dosing is typically reduced (eg, 30% reduction); refer to specific protocols (Rubie 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Malignancy, general dosing:</b> Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;10 kg: IV: 0.05 mg/<b>kg</b>/dose once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;10 kg: IV: 1.5 to 2 mg/m<sup>2</sup>/dose; frequency may vary based on protocol; maximum dose: 2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute lymphocytic leukemia (ALL) of infancy:</b> Limited data available: Infants &lt;1 year of age at diagnosis: IV: 1.5 mg/m<sup>2</sup>/dose; maximum dose 2 mg/dose; reported frequency variable but not more frequently than weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Pieters 2007</i>: Interfant-99 protocol: Administer on the following days: Induction phase: Days 8, 15, 22, and 29; Reinduction: Days 1, 8, 15, and 22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute lymphocytic leukemia (ALL), Standard-Risk and High-Risk:</b> Limited data available: Children and Adolescents: IV: 1.5 mg/m<sup>2</sup>/dose; maximum dose: 2 mg/dose; reported frequency variable but not more frequent than weekly:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Standard risk:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Avramis 2002:</i> Administer dose on the following days: Induction phase: Days 0, 7, 14, and 21; Consolidation phase: Days 0, 28, and 56; Interim maintenance phases: Days 0 and 28; Delayed intensification phase: Days 0, 7, and 14; Maintenance phase: Every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Bostrom 2003:</i> Administer dose on the following days: Induction phase: Days 0, 7, 14, and 21; Consolidation phase: Days 0, 28, and 56; Delayed intensification phase: Days 0, 7, and 14; Maintenance phase: Days 0, 28, and 56</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High-risk: <i>Larsen 2016</i>: Administer on the following days: Induction phase: Days 1, 8, 15, and 22; Extended Induction: Days 1 and 8; Consolidation: Days 15, 22, 43, and 50; Interim Maintenance 1: Days 1, 15, 29, and 42; Interim Maintenance 2: Days 1, 11, 21, 31, and 41; Delayed Intensification 1: Days 1, 8, 15, 43, and 50; Delayed Intensification 2: Days 1, 8, 15, 43, and 50; Maintenance phase: Every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ewing sarcoma:</b> Limited data available: Children and Adolescents: Dose and frequency regimens variable:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Grier 2003:</i> IV: 2 mg/m<sup>2</sup>/dose on day 1 of a 21-day cycle, administer either every cycle or during odd-numbered cycles; maximum dose: 2 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Kolb 2003:</i> IV: 0.67 mg/m<sup>2</sup>/<b>day</b> as a continuous IV infusion on days 1, 2, and 3; total dose for cycle: 2 mg/m<sup>2</sup>/<b>cycle</b> (maximum dose/cycle: 2 mg/dose/cycle) during cycles 1, 2, 3, and 6</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatoblastoma:</b> Limited data available: Infants, Children, and Adolescents: C5V Regimen: IV: 1.5 mg/m<sup>2</sup>/dose on Day 2 (in combination with 5-fluorouracil and cisplatin) (Evans 1982; Ortega 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hodgkin lymphoma:</b> Limited data available: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BEACOPP regimen: IV: 2 mg/m<sup>2</sup>/dose on day 7 of a 21-day treatment cycle; maximum dose: 2 mg/dose (Kelly 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;\">ABVE-PC (high risk and intermediate regimens) and AV-PC (low risk regimen): IV: 1.4 mg/m<sup>2</sup>/dose (maximum dose: 2.8 mg/dose) on Day 1 and 8 (Appel 2015; Friedman 2014; Schwartz 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Low-grade glioma, CNS tumor (low-grade ependymoma, infantile desmoplastic astrocytoma, etc)</b>: Limited data available: Children &lt;10 years: IV: 1.5 mg/m<sup>2</sup>/dose; maximum dose: 2 mg/dose; reported combination chemotherapy and frequency variable but not more frequent than weekly:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Ater 2012:</i> CV regimen: Administer on the following days: Induction phase: Days 0, 7, 14, 21, 28, 35, 42, 49, 56, and 63 of an 84-day cycle; Maintenance phase: Day 0, 7, and 14 of a 42-day cycle for 8 cycles (in combination with carboplatin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Ater 2012: </i>TPCV regimen: Administer on days 14 and 28 of a 42-day cycle (in combination with thioguanine, procarbazine, and lomustine) for a total of 8 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Medulloblastoma:</b> Limited data available: Children &lt;10 years: Head Start II Protocol: IV: 0.05 mg/<b>kg</b>/dose on Days 1, 8, and 15 of cycles 1 to 3 only (9 total doses) (Chi 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neuroblastoma:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low-dose cyclophosphamide-vincristine regimen: IV: 0.05 mg/<b>kg</b>/dose vincristine on day 1, and repeat in 14 days (Rubie 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CAdO regimen: IV: 0.05 mg/<b>kg</b>/dose on day 1 and 5, and repeat in 21 days (Rubie 2003; Rubie 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High-risk: Induction therapy: IV: 1.5 mg/m<sup>2</sup>/dose Day 1 in combination with doxorubicin and cyclophosphamide for cycles 2 and 5 (Seif 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Refractory: HD-CTV regimen: IV: 0.067 mg/<b>kg</b>/dose or 2 mg/m<sup>2</sup>/dose, whichever is lower; maximum dose: 2 mg/dose on day 1 (Kushner 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Non-Hodgkin Lymphoma</b>\n      <b> (</b>\n      <b>Burkitt lymphoma, Diffuse large B-cell lymphoma and B-cell ALL):</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Goldman 2013, Goldman 2014:</i> Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Reduction (COP regimen): IV: 1 mg/m<sup>2</sup>/dose; maximum dose: 2 mg/dose on Day 1</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction 1 and 2 (COPADM regimen): IV: 2 mg/m<sup>2</sup>/dose; maximum dose: 2 mg/dose on Day 1</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance 3 (COPA regimen): IV: 2 mg/m<sup>2</sup>/dose; maximum dose: 2 mg/dose on Day 1</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Reiter 1999:</i> Children and Adolescents: IV: 1.5 mg/m<sup>2</sup>/dose; maximum dose: 2 mg/dose; administer dose on day 1 of cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Retinoblastoma:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &le;36 months: IV: 0.05 mg/<b>kg</b>/dose; maximum dose: 2 mg/dose; reported frequency variable but not more frequent than weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Rodriguez-Galindo 2003:</i> Administer dose on day 1 every 21 days in combination with carboplatin for 8 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Friedman 2000:</i> Administer dose day 0 every 28 days in combination with carboplatin and etoposide for 6 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;36 months: IV: 1.5 mg/m<sup>2</sup> on day 0 every 28 days in combination with carboplatin and etoposide for 6 cycles; maximum dose: 2 mg/dose (Friedman 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhabdomyosarcoma:</b> Limited data available (Raney 2011; Walterhouse 2011; Walterhouse 2014); reported frequency variable but not more frequent than weekly: VA or VAC regimen:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: IV: 0.025 mg/<b>kg</b>/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to &lt;3 years: IV: 0.05 mg/<b>kg</b>/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;3 years and Adolescents: IV: 1.5 mg/m<sup>2</sup>/dose; maximum dose: 2 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Wilms tumor:</b> Limited data available (Green 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children weighing &le;30 kg: IV: 0.05 mg/<b>kg</b>/dose (maximum dose: 2 mg/dose) weeks 1, 2, 4, 5, 6, 7, 8, 10, and 11, followed by 0.067 mg/<b>kg</b>/dose (maximum dose: 2 mg/dose) weeks 12, 13, 18, and 24</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents weighing &gt;30 kg: IV: 1.5 mg/m<sup>2</sup>/dose (maximum dose: 2 mg) weeks 1, 2, 4, 5, 6, 7, 8, 10, and 11, followed by 2 mg/m<sup>2</sup>/dose (maximum dose: 2 mg) weeks 12, 13, 18, and 24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>General dosing:</b> Manufacturer's labeling: 1.4 mg/m<sup>2</sup>/dose; frequency may vary based on protocol; maximum dose: 2 mg/dose; refer to specific protocols</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for renal impairment:</b> Adults: No dosage adjustment necessary (Kintzel 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for hepatic impairment:</b> All patients: The manufacturer's labeling recommends the following adjustment: Serum bilirubin &gt;3 mg/dL: Administer 50% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The following adjustments have also been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Floyd 2006:</i> Serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN or alkaline phosphatase increased: Administer 50% of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Superfin 2007:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum bilirubin 1.5 to 3 mg/dL: Administer 50% of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum bilirubin &gt;3 mg/dL: Avoid use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234173\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vincasar PFS: 1 mg/mL (1 mL, 2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sulfate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (1 mL, 2 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234158\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050614\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: For IV administration only; fatal if given intrathecally;</b> vincristine should <span style=\"text-decoration: underline\">NOT</span> be delivered to the patient with any medications intended for central nervous system (ie, intrathecal) administration. <b>Note:</b><b> In order to prevent inadvertent intrathecal administration, the World Health Organization (WHO) and the Institute for Safe Medical Practices (ISMP) recommend dispensing vincristine in a minibag (rather than a syringe). </b>Vincristine should <span style=\"text-decoration: underline\">NOT</span> be prepared during the preparation of any intrathecal medication. After preparation, keep vincristine in a location away from the separate storage location recommended for intrathecal medications. If dispensing vincristine in a syringe, affix an auxiliary label stating <b>&quot;For intravenous use only - fatal if given by other routes&quot;</b> to the syringe and the syringe must be packaged in the manufacturer-provided overwrap which bears the statement <b>&quot;Do not remove covering until the moment of injection. For intravenous use only. Fatal if given intrathecally.&quot;</b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">IV infusion: Fatal if given intrathecally. The preferred administration is as a short infusion over 5 to 10 minutes in a minibag. If administration via a minibag is not possible, vincristine may also be administered undiluted (1 mg/mL) over 1 minute into a free flowing IV line to prevent venous irritation/extravasation. Some protocols utilize a 24-hour continuous IV infusion</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vincristine is a vesicant and should only be administered IV; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); apply dry warm compresses for 20 minutes 4 times a day for 1 to 2 days; elevate extremity (P&eacute;rez Fidalgo 2012). Remaining portion of the vincristine dose should be infused through a separate vein.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132727\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234188\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV solution: Diluted in 25 to 50 mL NS or D5W, stable for 7 days under refrigeration, or 2 days at room temperature. In ambulatory pumps, solution is stable for 7 days at room temperature. After preparation, keep vincristine in a location away from the separate storage location recommended for intrathecal medications. <b>Note:</b> Vincristine should be dispensed in a minibag (ISMP 2014). While dispensing vincristine in a syringe is NOT recommended, if prepared in a syringe, affix an auxiliary label stating <b>&ldquo;For intravenous use only - fatal if given by other routes&rdquo;</b> to the syringe, and the syringe must be dispensed in the manufacturer-provided overwrap which bears the statement <b>&quot;Do not remove covering until the moment of injection. For intravenous use only. Fatal if given intrathecally.&quot;</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050613\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, neuroblastoma, non-Hodgkin lymphomas, Wilms tumor, and rhabdomyosarcoma [FDA approved in pediatrics (age not specified) and adults]; has also been used in the treatment of central nervous system tumors, chronic lymphocytic leukemia (CLL), Ewing sarcoma, gestational trophoblastic tumors (high-risk), multiple myeloma, retinoblastoma, and small cell lung cancer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234253\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">VinCRIStine may be confused with vinBLAStine, vinorelbine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">VinCRIStine conventional may be confused with vinCRIStine liposomal</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Oncovin may be confused with Ancobon</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric patients: High-risk medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Vincristine is identified in the Beers Criteria as a potentially inappropriate medication to be used with caution in patients 65 years and older due to its potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">For IV use only. Fatal if administered by other routes. To prevent fatal inadvertent intrathecal injection, it is strongly recommended that vincristine doses be dispensed in a small minibag (25 to 50 mL of a compatible solution), and <b>NOT</b> a syringe (ISMP 2014). Vincristine should <b>NOT</b> be prepared during the preparation of any intrathecal medications. After preparation, keep vincristine in a location <b>away</b> from the separate storage location recommended for intrathecal medications. Vincristine should <b>NOT</b> be delivered to the patient at the same time with any medications intended for central nervous system administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234249\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema, hypertension, hypotension, ischemic heart disease, myocardial infarction, phlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal gait, ataxia, coma, cranial nerve dysfunction (auditory impairment, extraocular muscle impairment, laryngeal muscle impairment, motor dysfunction, paralysis, paresis, vestibular damage, vocal cord paralysis), decreased deep tendon reflex, dizziness, headache, neuralgia (common), neurotoxicity (dose-related), paralysis, paresthesia, parotid pain, peripheral neuropathy (common), seizure, sensorimotor neuropathy, sensory disturbance, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia (common), skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperuricemia, uric acid nephropathy (acute), weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, abdominal pain, anorexia, constipation (common), diarrhea, intestinal necrosis, intestinal perforation, nausea, oral mucosa ulcer, paralytic ileus, sore throat, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Bladder dysfunction (atony), dysuria, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (mild), hemolytic uremic syndrome, leukopenia (mild), thrombocytopenia (mild), thrombotic thrombocytopenic purpura</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local irritation (if infiltrated)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Amyotrophy, back pain, foot-drop, jaw pain, limb pain, myalgia, ostealgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Cortical blindness (transient), nystagmus, optic atrophy with blindness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Deafness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Polyuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, tissue necrosis (if infiltrated)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, hypersensitivity reaction, SIADH (syndrome of inappropriate antidiuretic hormone secretion)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234179\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patients with the demyelinating form of Charcot-Marie-Tooth syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for drugs in this class is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234162\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation:<b> [US Boxed Warning]: Vincristine is a vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation. Individuals administering should be experienced in vincristine administration. Extravasation may cause significant irritation. If extravasation occurs, discontinue immediately and initiate appropriate extravasation management, including local injection of hyaluronidase and moderate heat application to the affected area. Use a separate vein to complete administration.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal effects: Constipation, paralytic ileus, intestinal necrosis and/or perforation may occur; constipation may present as upper colon impaction with an empty rectum (may require flat film of abdomen for diagnosis); generally responds to high enemas and laxatives. All patients should be on a prophylactic bowel management regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: Alterations in mental status such as depression, confusion, or insomnia may occur; neurologic effects are dose-limiting (may require dosage reduction) and may be additive with those of other neurotoxic agents and spinal cord irradiation. Use with caution in patients with pre-existing neuromuscular disease and/or with concomitant neurotoxic agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory effects: Acute shortness of breath and severe bronchospasm have been reported with vinca alkaloids, usually when used in combination with mitomycin. Onset may be several minutes to hours after vincristine administration and up to 2 weeks after mitomycin. Progressive dyspnea may occur. Permanently discontinue vincristine if pulmonary dysfunction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Uric acid nephropathy: Acute uric acid nephropathy has been reported with vincristine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage modification required. May be associated with hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]), increased risk in children &lt;3 years of age; use with caution in hepatobiliary dysfunction. Monitor for signs or symptoms of hepatic SOS, including bilirubin &gt;1.4 mg/dL, unexplained weight gain, ascites, hepatomegaly, or unexplained right upper quadrant pain (Arndt 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hazardous agent: Avoid eye contamination.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Not for intrathecal administration: <b>[US Boxed Warning]: For IV administration only; inadvertent intrathecal administration usually results in death.</b> To prevent administration errors, the Institute for Safe Medication Practices (ISMP) Targeted Medication Safety Best Practices for Hospitals initiative and the World Health Organization strongly recommend dispensing vincristine diluted in a minibag (ISMP 2014, WHO 2007), <b>if not dispensed in a minibag, affix an auxiliary label stating &ldquo;For intravenous use only - fatal if given by other routes&rdquo; and also place in an overwrap labeled &ldquo;Do not remove covering until moment of injection.&rdquo;</b> Vincristine should <b>NOT</b> be prepared during the preparation of any intrathecal medications. After preparation, keep vincristine in a location <b>away</b> from the separate storage location recommended for intrathecal medications. Vincristine should <b>NOT</b> be delivered to the patient at the same time with any medications intended for central nervous system administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234239\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234167\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12882&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May enhance the adverse/toxic effect of VinCRIStine. Itraconazole may increase the serum concentration of VinCRIStine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May increase the serum concentration of VinCRIStine. Management: Monitor closely for signs and symptoms of vincristine toxicity; consider temporary interruption of lopinavir/ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues. Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MitoMYcin (Systemic): Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: May increase the serum concentration of VinCRIStine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of VinCRIStine. VinCRIStine may decrease the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Management: Avoid the concomitant use of posaconazole and vinca alkaloids when possible. If combined, monitor for increased vinca alkaloid toxicities (eg, neurotoxicity, gastrointestinal toxicity).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of VinCRIStine. Management: Monitor closely for signs and symptoms of vincristine toxicity; consider temporary interruption of ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teniposide: May enhance the neurotoxic effect of VinCRIStine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234169\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10517724\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have demonstrated teratogenicity and fetal loss. May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant during treatment. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050609\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum electrolytes (sodium, hepatic function tests, neurologic examination (prior to each dose), serum uric acid, monitor infusion site, monitor for constipation/ileus and for signs/symptoms of peripheral neuropathy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234161\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Vincristine binds to tubulin and inhibits microtubule formation, therefore, arresting the cell at metaphase by disrupting the formation of the mitotic spindle; it is specific for the M and S phases. Vincristine may also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234178\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> In pediatric patients, significant intrapatient and interpatient variability has been reported (Gidding 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Rapidly removed from bloodstream and tightly bound to tissues; penetrates blood-brain barrier poorly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic, via CYP3A4</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: 85 hours (range: 19 to 155 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (~80%); urine (10% to 20%; &lt;1% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance: In pediatric patients, correlation with diagnosis has been reported; clearance in patients with ALL and non-Hodgkin lymphoma higher than Wilms&rsquo; tumor (Gidding 1999):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: Vincristine clearance is lower compared to children; more closely related to body weight than to body surface area (Crom1994)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents 2 to 18 years: Reported means: 357 to 482 mL/minute/m<sup>2</sup>; some suggest faster clearance in children &lt;10 years of age than in adolescents (Crom 1994); however, more recent data does not support this finding nor a dosage reduction in adolescent patients (Frost 2003; Gidding 1999)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324097\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vincasar PFS Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1 mL): $18.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (VinCRIStine Sulfate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1 mL): $6.79</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234181\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alcavixin (PH);</li>\n      <li>Biocristin (IN);</li>\n      <li>Cellicristin (LB);</li>\n      <li>Citomid (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Citomid RU (MX, TH);</li>\n      <li>Cristol (ET);</li>\n      <li>Criston (BD);</li>\n      <li>Cristovin (IL);</li>\n      <li>Crivosin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Cytocristin (BG, IN, VN, ZW);</li>\n      <li>Farmistin CS (DE);</li>\n      <li>Kyocristine (JP);</li>\n      <li>Oncocristin (CO, PE);</li>\n      <li>Oncovin (AE, AT, AU, BF, BH, BJ, CH, CI, CR, CZ, DE, DK, DO, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, GT, HN, HR, IE, IT, KE, LR, LU, MA, ML, MR, MT, MU, MW, MX, NE, NG, NI, NL, NO, PA, PK, PL, PT, QA, RU, SA, SC, SD, SE, SK, SL, SN, SV, TN, TR, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Rasteo (ID);</li>\n      <li>Tecnocris (BR);</li>\n      <li>Vinces (AR);</li>\n      <li>Vincran (KR);</li>\n      <li>Vincrina (PY);</li>\n      <li>Vincrisin (BE);</li>\n      <li>Vincristin (HU, PL);</li>\n      <li>Vincristina (IT);</li>\n      <li>Vincristine Delta West (HR);</li>\n      <li>Vincristine Sulfate (PL);</li>\n      <li>Vincristine-David Bull (LU);</li>\n      <li>Vinracine (HK, MY, SG);</li>\n      <li>Vinstin (LK);</li>\n      <li>Vintec (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Appel BE, Chen L, Buxton AB, et al. Minimal treatment of low-risk, pediatric lymphocyte-predominant Hodgkin Lymphoma: a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2016;34(20):2372-2379.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/27185849/pubmed\" target=\"_blank\" id=\"27185849\">27185849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arndt C, Hawkins D, Anderson JR, et al, &quot;Age Is a Risk Factor for Chemotherapy-Induced Hepatopathy With Vincristine, Dactinomycin, and Cyclophosphamide,&quot; <i>J Clin Oncol</i>, 2004, 22(10):1894-901.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/15143082/pubmed\" target=\"_blank\" id=\"15143082\">15143082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007, 120, 174.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ater JL, Zhou T, Holmes E, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2012;30(21):2641-2647.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/22665535/pubmed\" target=\"_blank\" id=\"22665535\">22665535</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avramis VI, Sencer S, Periclou AP, et, al, &quot;A Randomized Comparison of Native Escherichia Coli Asparaginase and Polyethylene Glycol Conjugated Asparaginase for Treatment of Children With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia: A Children's Cancer Group Study,&quot; <i>Blood</i>, 2002, 99(6):1986-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/11877270/pubmed\" target=\"_blank\" id=\"11877270\">11877270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bostrom BC, Sensel MR, Sather HN, et al, &quot;Dexamethasone Versus Prednisone and Daily Oral Versus Weekly Intravenous Mercaptopurine for Patients With Standard-Risk Acute Lymphoblastic Leukemia: A Report From the Children's Cancer Group,&quot; <i>Blood</i>, 2003, 101(10):3809-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12531809/pubmed\" target=\"_blank\" id=\"12531809\">12531809</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bowman WP, Shuster JJ, Cook B, et al, &ldquo;Improved Survival for Children With B-Cell Acute Lymphoblastic Leukemia and Stage IV Small Noncleaved-Cell Lymphoma: A Pediatric Oncology Group Study,&rdquo; <i>J Clin Oncol</i>, 1996, 14(4):1252-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/8648381/pubmed\" target=\"_blank\" id=\"8648381\">8648381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cairncross G, Berkey B, Shaw E, et al, &quot;Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402,&quot; <i>J Clin Oncol</i>, 2006, 24(18):2707-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16782910/pubmed\" target=\"_blank\" id=\"16782910\">16782910</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. <i>J Clin Oncol</i>. 2004;22(24):4881-4887.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/15611503/pubmed\" target=\"_blank\" id=\"15611503\">15611503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crist WM, Anderson JR, Meza JL, et al, &quot;Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease,&quot; <i>J Clin Oncol</i>, 2001, 19(12):3091-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/11408506/pubmed\" target=\"_blank\" id=\"11408506\">11408506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crom WR, deGraaf SS, Synold T, et al, &ldquo;Pharmacokinetics of Vincristine in Children and Adolescents With Acute Lymphocytic Leukemia,&rdquo; <i>J Pediatr</i>, 1994, 125(4):642-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/7931891/pubmed\" target=\"_blank\" id=\"7931891\">7931891</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diehl V, Franklin J, Pfreundschuh M, et al, &quot;Standard and Increased-Dose BEACOPP Chemotherapy Compared With COPP-ABVD for Advanced Hodgkin's Disease,&quot; <i>N Engl J Med</i>, 2003, 348(24):2386-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12802024/pubmed\" target=\"_blank\" id=\"12802024\">12802024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evans AE, Land VJ, Newton WA, Randolph JG, Sather HN, Tefft M. Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoma. <i>Cancer</i>. 1982;50(5):821-826.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/6284345/pubmed\" target=\"_blank\" id=\"6284345\">6284345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd JD, Nguyen DT, Lobins RL, et al, &quot;Cardiotoxicity of Cancer Therapy,&quot; <i>J Clin Oncol</i>. 2005, 23(30):7685-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16234530/pubmed\" target=\"_blank\" id=\"16234530\">16234530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd J, Mirza I, Sachs B, et al, &quot;Hepatotoxicity of Chemotherapy,&quot; <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16473644/pubmed\" target=\"_blank\" id=\"16473644\">16473644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. <i>J Clin Oncol</i>. 2014;32(32):3651-3658.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/25311218/pubmed\" target=\"_blank\" id=\"25311218\">25311218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedman DL, Himelstein B, Shields CL, et al, &quot;Chemoreduction and Local Ophthalmic Therapy for Intraocular Retinoblastoma,&quot; <i>J Clin Oncol</i>, 2000, 18(1):12-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/10623688/pubmed\" target=\"_blank\" id=\"10623688\">10623688</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frost BM, L&ouml;nnerholm G, Koopmans P, et al, &quot;Vincristine in Childhood Leukaemia: No Pharmacokinetic Rationale for Dose Reduction in Adolescents,&quot; <i>Acta Paediatr</i>, 2003, 92(5):551-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12839283/pubmed\" target=\"_blank\" id=\"12839283\">12839283</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, Uges DR, Kamps WA, de Graaf SS. Vincristine pharmacokinetics after repetitive dosing in children. <i>Cancer Chemother Pharmacol</i>. 1999;44(3):203-209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/10453721/pubmed\" target=\"_blank\" id=\"10453721\">10453721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. <i>Leukemia</i>. 2013;27(5):1174-1177.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/22940833/pubmed\" target=\"_blank\" id=\"22940833\">22940833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. <i>Br J Haematol</i>. 2014;167(3):394-401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/25066629/pubmed\" target=\"_blank\" id=\"25066629\">25066629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Granowetter L, Womer R, Devidas M, et al, &quot;Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study,&quot; <i>J Clin Oncol</i>, 2009, 27(15):2536-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/19349548/pubmed\" target=\"_blank\" id=\"19349548\">19349548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Green DM, Cotton CA, Malogolowkin M, et al, &quot;Treatment of Wilms Tumor Relapsing After Initial Treatment With Vincristine and Actinomycin D: A Report From the National Wilms Tumor Study Group,&quot; <i>Pediatr Blood Cancer</i>, 2007, 48(5):493-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16547940/pubmed\" target=\"_blank\" id=\"16547940\">16547940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grier HE, Krailo MD, Tarbell NJ, et al, &quot;Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone,&quot; <i>N Engl J Med</i>, 2003, 348(8):694-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12594313/pubmed\" target=\"_blank\" id=\"12594313\">12594313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horning SJ, Hoppe RT, Breslin S, et al, &quot;Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial,&quot; <i>J Clin Oncol</i>, 2002, 20(3):630-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/11821442/pubmed\" target=\"_blank\" id=\"11821442\">11821442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horning SJ, Williams J, Bartlett NL, et al, &quot;Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492,&quot; <i>J Clin Oncol</i>, 2000, 18(5):972-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/10694546/pubmed\" target=\"_blank\" id=\"10694546\">10694546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices. 2014-2015 Targeted Medication Safety Best Practices for Hospitals. Available at http://www.ismp.org/tools/bestpractices/TMSBP-for-Hospitals.pdf. Accessed June 19, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson JO, Polovich M, McNiff KK, et al, &quot;American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards,&quot; <i>J Clin Oncol</i>, 2009, 27(32):5469-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/19786650/pubmed\" target=\"_blank\" id=\"19786650\">19786650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian H, Thomas D, O'Brien S, et al, &quot;Long-Term Follow-Up Results of Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD), A Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia,&quot; <i>Cancer</i>, 2004, 101(12):2788-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/15481055/pubmed\" target=\"_blank\" id=\"15481055\">15481055</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly KM, Hutchinson RJ, Sposto R, et al, &quot;Feasibility of Upfront Dose-Intensive Chemotherapy in Children With Advanced-Stage Hodgkin's Lymphoma: Preliminary Results From the Children's Cancer Group Study CCG-59704,&quot; <i>Ann Oncol</i>, 2002, 13(Suppl 1):107-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12078889/pubmed\" target=\"_blank\" id=\"12078889\">12078889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kolb EA, Kushner BH, Gorlick R, et al, &quot;Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing's Family of Tumors in Children and Young Adults,&quot; <i>J Clin Oncol</i>, 2003, 21(18):3423-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12972518/pubmed\" target=\"_blank\" id=\"12972518\">12972518</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BH, Kramer K, Modak S, Qin LX, Cheung NK. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. <i>Cancer</i>. 2010;116(12):3054-3060.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/20564411/pubmed\" target=\"_blank\" id=\"20564411\">20564411</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BH, LaQuaglia MP, Bonilla MA, et al, &ldquo;Highly Effective Induction Therapy for Stage 4 Neuroblastoma in Children Over 1 Year of Age,&rdquo; <i>J Clin Oncol</i>, 1994, 12(12):2607-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/7527454 /pubmed\" target=\"_blank\" id=\"7527454 \">7527454 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group Study AALL0232. <i>J Clin Oncol</i>. 2016;34(20):2380-2388.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/27114587/pubmed\" target=\"_blank\" id=\"27114587\">27114587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larson RA, Dodge RK, Burns CP, et al, &quot;A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811,&quot; <i>Blood</i>, 1995, 85(8):2025-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/7718875/pubmed\" target=\"_blank\" id=\"7718875\">7718875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Legha SS, &quot;Vincristine Neurotoxicity. Pathophysiology and Management,&quot; <i>Med Toxicol</i>, 1986, 1(6):421-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/3540519/pubmed\" target=\"_blank\" id=\"3540519\">3540519</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magrath I, Adde M, Shad A, et al, &ldquo;Adults and Children With Small Non-Cleaved-Cell Lymphoma Have a Similar Excellent Outcome When Treated With the Same Chemotherapy Regimen,&rdquo; <i>J Clin Oncol</i>, 1996, 14(3):925-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/8622041 /pubmed\" target=\"_blank\" id=\"8622041 \">8622041 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCune JS and Lindley C, &quot;Appropriateness of Maximum-Dose Guidelines for Vincristine,&quot; <i>Am J Health Syst Pharm</i>, 1997, 54(15):1755-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/9262750/pubmed\" target=\"_blank\" id=\"9262750\">9262750</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mead GM, Barrans SL, Qian W, et al, &quot;A Prospective Clinicopathologic Study of Dose-Modified CODOX-M/IVAC in Patients With Sporadic Burkitt Lymphoma Defined Using Cytogenetic and Immunophenotypic Criteria (MRC/NCRI LY10 Trial),&quot; <i>Blood</i>, 2008, 112(6):2248-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/18612102/pubmed\" target=\"_blank\" id=\"18612102\">18612102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mead GM, Sydes MR, Walewski J, et al, &quot;An International Evaluation of CODOX-M and CODOX-M Alternating With IVAC in Adult Burkitt's Lymphoma: Results of United Kingdom Lymphoma Group LY06 Study,&quot; <i>Ann Oncol</i>, 2002, 13(8):1264-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12181251/pubmed\" target=\"_blank\" id=\"12181251\">12181251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moore A and Pinkerton R, &quot;Vincristine: Can Its Therapeutic Index Be Enhanced?&quot; <i>Pediatr Blood Cancer</i>, 2009, 53(7):1180-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/19588521/pubmed\" target=\"_blank\" id=\"19588521\">19588521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan C, Tillett T, Braybrooke J, et al, &quot;Management of Uncommon Chemotherapy-Induced Emergencies,&quot; <i>Lancet Oncol</i>, 2011, 12(8):806-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/21276754/pubmed\" target=\"_blank\" id=\"21276754\">21276754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. <i>J Clin Oncol</i>. 2000;18(14):2665-2675.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/10894865/pubmed\" target=\"_blank\" id=\"10894865\">10894865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo; <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. <i>Lancet</i>. 2007;370(9583):240-250.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/17658395/pubmed\" target=\"_blank\" id=\"17658395\">17658395</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pritchard J, Imeson J, Barnes J, et al, &quot;Results of the United Kingdom Children's Cancer Study Group First Wilms' Tumor Study,&quot; <i>J Clin Oncol</i>, 1995, 13(1):124-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/7799012/pubmed\" target=\"_blank\" id=\"7799012\">7799012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raney RB, Walterhouse DO, Meza JL, et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. <i>J Clin Oncol</i>. 2011;29(10):1312-1318.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/21357783/pubmed\" target=\"_blank\" id=\"21357783\">21357783</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reiter A, Schrappe M, Tiemann M, et al, &ldquo;Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-M&uuml;nster Group Trial NHL-BFM 90,&rdquo; <i>Blood</i>, 1999, 94(10):3294-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/10552938/pubmed\" target=\"_blank\" id=\"10552938\">10552938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodriguez-Galindo C, Wilson MW, Haik BG, et al, &quot;Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin,&quot; <i>J Clin Oncol</i>, 2003, 21(10):2019-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12743157/pubmed\" target=\"_blank\" id=\"12743157\">12743157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubie H, Coze C, Plantaz D, et al. Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy. <i>Br J Cancer</i>. 2003;89(9):1605-1609.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/14583756/pubmed\" target=\"_blank\" id=\"14583756\">14583756</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubie H, De Bernardi B, Gerrard M, et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. <i>J Clin Oncol</i>. 2011;29(4):449-455.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/21172879/pubmed\" target=\"_blank\" id=\"21172879\">21172879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubie H, Michon J, Plantaz D, et al, &ldquo;Unresectable Localized Neuroblastoma: Improved Survival After Primary Chemotherapy Including Carboplatin-Etoposide. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP),&rdquo; <i>Br J Cancer</i>, 1998, 77(12):2310-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/9649151 /pubmed\" target=\"_blank\" id=\"9649151 \">9649151 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubie H, Plantaz D, Coze C, et al, &quot;Localised and Unresectable Neuroblastoma in Infants: Excellent Outcome With Primary Chemotherapy. Neuroblastoma Study Group, Soci&eacute;t&eacute; Fran&ccedil;aise d'Oncologie P&eacute;diatrique,&quot; <i>Med Pediatr Oncol</i>, 2001, 36(1):247-50.S<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/11464897/pubmed\" target=\"_blank\" id=\"11464897\">11464897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. <i>Blood</i>. 2009;114(10):2051-2059.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/19584400/pubmed\" target=\"_blank\" id=\"19584400\">19584400</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seif AE, Naranjo A, Baker DL, et al. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. <i>Bone Marrow Transplant</i>. 2013;48(7):947-952.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/23334272/pubmed\" target=\"_blank\" id=\"23334272\">23334272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shields CL, Honavar SG, Meadows AT, et al, &quot;Chemoreduction for Unilateral Retinoblastoma,&quot; <i>Arch Ophthalmol</i>, 2002, 120(12):1653-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12470138/pubmed\" target=\"_blank\" id=\"12470138\">12470138</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stefanou A and Dooley M, &quot;Simple Method to Eliminate the Risk of Inadvertent Intrathecal Vincristine Administration,&quot; <i>J Clin Oncol</i>, 2003, 21(10):2044.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/12743160/pubmed\" target=\"_blank\" id=\"12743160\">12743160</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Superfin D, Iannucci AA, and Davies AM, &quot;Commentary: Oncologic Drugs in Patients With Organ Dysfunction: A Summary,&quot; <i>Oncologist</i>, 2007, 12(9):1070-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/17914077/pubmed\" target=\"_blank\" id=\"17914077\">17914077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thomas DA, Faderi S, O&rsquo;Brien S, et al, &ldquo;Chemoimmunotherapy With Hyper-CVAD Plus Rituximab for the Treatment of Adult Burkitt and Burkitt-Type Lymphoma or Acute Lymphoblastic Leukemia,&rdquo; <i>Cancer</i>, 2006, 106(7):1569-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/16502413/pubmed\" target=\"_blank\" id=\"16502413\">16502413</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walterhouse DO, Meza JL, Breneman JC, et al. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group. <i>Pediatr Blood Cancer</i>. 2011;57(1):76-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/21298768/pubmed\" target=\"_blank\" id=\"21298768\">21298768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walterhouse DO, Pappo AS, Meza JL, et al. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. <i>J Clin Oncol</i>. 2014;32(31):3547-3552.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/25267746/pubmed\" target=\"_blank\" id=\"25267746\">25267746</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilson WH, Grossbard ML, Pittaluga S, et al, &ldquo;Dose-Adjusted EPOCH Chemotherapy for Untreated Large B-Cell Lymphomas: A Pharmacodynamic Approach With High Efficacy,&rdquo; <i>Blood</i>, 2002, 99(8):2685-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/11929754/pubmed\" target=\"_blank\" id=\"11929754\">11929754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Woods WG, O'Leary M, and Nesbit ME, &ldquo;Life-Threatening Neuropathy and Hepatotoxicity in Infants During Induction Therapy for Acute Lymphoblastic Leukemia,&rdquo; <i>J Pediatr</i>, 1981, 98(4):642-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vincristine-conventional-pediatric-drug-information/abstract-text/6937637/pubmed\" target=\"_blank\" id=\"6937637\">6937637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, &quot;Vincristine (and Other Vinca Alkaloids) Should Only Be Given Intravenously Via a Minibag,&quot; July, 2007, Alert 115. Available at http://www.who.int/medicines/publications/drugalerts/Alert_115_vincristine.pdf</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12882 Version 165.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708854\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F234194\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F10518612\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1050610\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F16342255\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1050602\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F234173\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F234158\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1050614\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132727\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F234188\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1050613\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F234253\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F234249\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F234179\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F234162\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F234239\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F234167\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F234169\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10517724\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1050609\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F234161\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F234178\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324097\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F234181\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12882|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vincristine-conventional-drug-information\" class=\"drug drug_general\">Vincristine (conventional): Drug information</a></li><li><a href=\"topic.htm?path=vincristine-conventional-patient-drug-information\" class=\"drug drug_patient\">Vincristine (conventional): Patient drug information</a></li></ul></div></div>","javascript":null}